What is it about?
A significant number of patients undergoing treatment with selective serotonin reuptake inhibitors (SSRIs) report sexual dysfunction. SSRI-induced sexual dysfunction adversely affects quality of life and patient adherence to and compliance with treatment regimens. This trial examined the efficacy and safety of adjunctive bupropion in the treatment of SSRI-induced female sexual dysfunction. Sexual function was assessed by using the sexual function domains of the Female Sexual Function Index (primary efficacy outcome measure) and the Clinical Global Impression Scale adapted for sexual function (secondary efficacy outcome measure).
Photo by Nathan Dumlao on Unsplash
Why is it important?
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed to treat depression, anxiety, and premenstrual disorders in women. Female sexual dysfunction (FSD) is a highly prevalent health problem per se. The incidence of sexual dysfunction with SSRIs is high, ranging from 30% to 70%. SSRI treatment-emergent sexual dysfunction is a principal reason for poor treatment adherence and treatment compliance. Up to 90% of patients with SSRI-induced sexual dysfunction will discontinue their medication prematurely. Treatment-emergent sexual dysfunction caused by antidepressants varies considerably across compounds. It should be considered in the choice of the administered drug. Among the sexual side effects most often associated with SSRIs in women are inhibited or decreased sexual desire, inhibited sexual excitement, and difficulty in achieving orgasm.
Read the Original
This page is a summary of: Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study, Journal of Psychopharmacology, January 2010, SAGE Publications, DOI: 10.1177/0269881109351966.
You can read the full text:
The following have contributed to this page